Introduction {#Sec1}
============

Alcohol and nicotine are the two most widely abused addictive substances. While several pharmacological treatments for alcohol and nicotine dependence are targeted at reducing drug intake, these treatments generally demonstrate limited protection against relapse (Anton et al. [@CR1]; Frishman [@CR17]). In this respect, varenicline, a novel agent currently prescribed to aid smoking cessation, may have a more favourable pharmacological profile than other registered pharmacotherapeuticals, such as bupropion (Gonzales et al. [@CR18]; Jorenby et al. [@CR22]). Varenicline is a partial α4β2 nicotinic receptor agonist and was developed with the assumption that such agents may possibly diminish the consequences of both nicotine exposure and its absence. Partial α4β2 nicotinic receptor agonists are postulated to promote smoking cessation by preventing nicotine from binding to the receptor. At the same time, by partial activation of α4β2 nicotinic receptors, such agents would moderately increase mesolimbic dopamine release, which is believed to alleviate craving (Coe et al. [@CR6]; Niaura et al. [@CR34]). Indeed, clinical observations indicate that varenicline is able to (1) reduce withdrawal symptoms and negative affect during abstinence in treatment-seeking smokers, (2) attenuate the subjective rewarding effects of nicotine during a scheduled smoking lapse and (3) increase the number of abstinent days following the smoking lapse in a subgroup of participants (Patterson et al. [@CR37]). Consistent with these clinical findings, preclinical evidence confirms that varenicline effectively reduces nicotine self-administration in rats (O\'Connor et al. [@CR36]; Rollema et al. [@CR41]). Furthermore, in a rat model for relapse, varenicline attenuated nicotine primed relapse to nicotine seeking as well as relapse induced by a combination of a nicotine prime and associated cues. In contrast, varenicline had no effect on cue-induced relapse alone (O\'Connor et al. [@CR36]).

Interestingly, recent findings suggest that varenicline may also modulate alcohol seeking and intake in heavy drinking smokers as well as laboratory animals (McKee et al. [@CR29]; Steensland et al. [@CR47]). Consistent with these findings, varenicline was shown to counteract alcohols\' enhancing effect on dopamine levels in the nucleus accumbens in rats (Ericson et al. [@CR15]). Lowering dopamine levels in this region has previously been associated with reduced alcohol consumption in rats (Ericson et al. [@CR13], [@CR14]; Soderpalm et al. [@CR45]). Together, these findings underline the potential of varenicline as a treatment for alcohol use disorders in addition to its efficacy as a smoking cessation aid.

In humans, abstinence and relapse are associated with cognitive deficits (Scheurich [@CR43]). Therefore, cognitive enhancing agents are pursuit as pharmacotherapy targets for addiction (Sofuoglu [@CR46]). In this respect, nicotine receptor (nAChR) agonists are interesting targets, since acute and chronic administration of nAchR agonists can produce long-lasting cognitive enhancing effects (Buccafusco et al. [@CR3]), such as improvement of working and spatial memory, facilitated associative learning and improved attentional processing (Levin et al. [@CR26]; Rezvani and Levin [@CR39]). For that reason, the putative cognitive enhancing effects of varenicline warrant investigation.

In the current study, we aim to further elucidate the motivational and cognitive effects of varenicline, with a particular focus on the relapse-preventing properties of this compound in an alcohol seeking and taking model. To that end, we tested the effects of varenicline on both self-administration and relapse to alcohol and nicotine seeking. Moreover, to control for drug specificity, we also evaluated the effects of varenicline on self-administration of the natural reinforcer sucrose. Finally, we employed the 5-choice serial reaction time task (5-CSRTT) to assess possible cognitive enhancing effects of varenicline at the level of visuospatial attention and inhibitory response control (Robbins [@CR40]), the latter being a behavioural trait associated with enhanced motivation to initiate and maintain nicotine self-administration in rats (Diergaarde et al. [@CR12]).

Methods {#Sec2}
=======

Animals {#Sec3}
-------

Male Wistar rats (Harlan CPB, Horst, The Netherlands), weighing 280--320 g upon arrival, were used. They were housed in pairs in a temperature- and humidity-controlled room on a 12-h light/dark cycle (lights on between 7 p.m. and 7 a.m.), with the exception that animals that were implanted with intravenous silicon catheters were individually housed. Catheters were implanted in the right jugular vein under gas anaesthesia (Isoflurane) as described before (De Vries et al. [@CR10]). All training and testing sessions were conducted during the dark phase of the light--dark cycle, at the same time each day. Experimental procedures were approved by the Animal Ethical Committee of the VU University, Amsterdam, The Netherlands.

Apparatus and behavioural procedure {#Sec4}
-----------------------------------

### Self-administration {#Sec5}

Self-administration training and testing was conducted in 32 identical operant chambers enclosed in sound-attenuating ventilated cubicles (Med Associates Inc., St. Albans, VT, USA). The operant chambers were equipped with a grid floor, two nose poke holes and a central reinforcer receptacle; a dim red house light and a tone module (ENV-223AM Med Associates Inc.) were fitted on the opposite wall. During self-administration, reinforcers were delivered by an infusion pump (PHM-100, Med Associates Inc.).

Animals were placed in the operant chamber, and after 30 s, the house light was switched on and trials started. Each trial was signalled by illumination of a red stimulus light located above the active hole, which was extinguished when a nose poke was made into this hole. An active nose poke resulted either in an intravenous (i.v.) infusion of nicotine (40 μg/kg), the delivery of 0.2 ml alcohol (12%, *v*/*v*) or 0.2 ml 10% sucrose in the receptacle, and a yellow stimulus light in the nose poke hole was illuminated for 5 s combined with a 2-s tone signal (±68 dB, 2,900 Hz). After delivery, a time-out period of 15 s commenced, during which, all stimulus lights were switched off until the next trial started. Responding during time-out was monitored, but had no programmed consequences.

### Two-bottle procedure {#Sec6}

To facilitate acquisition of operant alcohol self-administration, rats were first trained to consume alcohol in a two-bottle free-access paradigm. In this paradigm, upon arrival, rats were habituated to two water bottles on their home cages. Every other day, one of the bottles was replaced by a bottle containing a gradually increasing alcohol solution (from 2% to 12%, *v*/*v*). In three weeks, the animals reached 12%, *v*/*v* alcohol, and training proceeded to a two-bottle limited-access paradigm, i.e. animals were given access to the 12% solution for 1 h daily. After 10 days of limited access, animals that consumed over 0.35 g/kg alcohol were selected to enter the operant self-administration phase.

### 5-Choice serial reaction time task {#Sec7}

Experiments were conducted in rat operant chambers with stainless steel grid floors (MED-NPW-5L; Med Associates Inc.). On-line control of all operant chambers and data collection were performed using MED-PC version IV (Med Associates Inc.). Five sessions were scheduled per week from Monday until Friday, one session per day.

A more detailed description of training in the 5-CSRTT has been reported previously (van Gaalen et al. [@CR50]). In short, rats were trained to detect and respond to a 1-s visual stimulus in either one of five apertures, during presentation of the stimulus or during the 2-s limited hold period, to obtain a food pellet (45 mg, Formula P; Research Diets Inc., New Brunswick, NJ, USA). Each session terminated after 100 trials or 30 min, whichever occurred first. Initially, the duration of this stimulus was 32 s and was gradually decreased to 1 s over sessions until animals reached stable baseline performance (accuracy \>80% correct choice and \<20% errors of omission). Incorrect, premature responses (responses during the 5-s inter-trial interval (ITI)) and errors of omission did not lead to the delivery of a food pellet and resulted in a 5-s time-out period, during which, the house light was extinguished. Responses during the time-out period resulted in a new time-out period. Perseverative responses, i.e. repeated responding into an aperture following correct choice and before pellet collection, were measured but did not have any programmed consequences. The following behavioural measures were recorded: (1) accuracy ((number correct trials/(correct + incorrect trials)) 100); (2) latency of correct responses, i.e. the mean time between stimulus onset and nose poke in the illuminated unit; (3) premature responses, i.e. the number of premature responses before the onset of the visual stimulus, reflecting aspects of loss of inhibitory control (impulsivity) and (4) perseverative responses after correct choice, a measure of compulsive behaviour; (5) omission errors, i.e. the total number of omitted trials during a session.

Experimental design {#Sec8}
-------------------

### Self-administration {#Sec9}

In three separate experiments, we tested the effects of varenicline on either nicotine (exp 1), alcohol (exp 2) or sucrose (exp 3) self- administration. Behavioural training started 1 week after surgery (nicotine), two-bottle procedure (alcohol) or arrival (sucrose). Initially, all animals were trained daily in 1-h sessions on a continuous reinforcement schedule. The fixed ratio was increased during training, up to FR3 for the nicotine groups and FR4 for alcohol and sucrose groups. When the levels of responding met predefined selection criteria, the effect of a graded dose of varenicline on self-administration was tested. Criterion performance was defined as follows. For the nicotine group, animals that received five or more reinforcers, distributed over the session during the last three sessions on a FR3 schedule, were selected for testing. In the alcohol group, animals that self-administered over 0.35 g/kg alcohol for three consecutive days on a FR4 schedule of reinforcement were selected for testing. In the sucrose group, all animals received five or more reinforcers, distributed over the session during the last three sessions on a FR4 schedule and were selected for testing.

Varenicline tests were conducted twice a week, on Tuesdays and Fridays. On intermediate days, rats were trained to self-administer nicotine, alcohol or sucrose without being treated with varenicline. To explore the effects of varenicline on self-administration, a within-subject design was used, and treatment was randomized over the subjects using a Latin square design.

To facilitate acquisition, the alcohol group (exp 2) was given a single 20-min habituation session on the first training day, during which, only the house light was illuminated. Nose poking during this session was without any behavioural consequences. Furthermore, these animals received one free sample of alcohol in the central receptacle upon the start of the habituation session and the first five training sessions.

### Cue-induced relapse {#Sec10}

To asses the effects of varenicline on cue-induced relapse to nicotine or alcohol seeking, two separate groups of animals were trained to criterion performance and subsequently underwent extinction training. Thus, animals were placed in the training context for 15 daily sessions of 1 h, without audiovisual cue-exposure or reinforcer delivery.

**Relapse** Rats were divided into four experimental groups that received either vehicle, 0.5, 1.5 or 2.5 mg/kg varenicline. On the test day, all animals were injected with vehicle or one of three doses 30 min before they were placed in the training context for a 30-min relapse test. During the relapse test, the house light and red cue light were turned on, and nose poking resulted in the presentation of the discrete compound audiovisual cues (but no reinforcer delivery) on the FR schedule used during training. In the alcohol group, 0.20 ml alcohol (12%, *v*/*v*) was delivered in the receptacle before the session started. We conducted a series of pilot studies investigating cue-induced alcohol seeking under several conditions. Data from these studies and work by others indicate that adding a single drop of alcohol, that induces the gustatory, but not the pharmacological effects of alcohol, results in optimal relapse (Le and Shaham [@CR25]).

### 5-Choice serial reaction time task {#Sec11}

To assess putative cognitive enhancing effects of varenicline, rats were trained in the 5-CSRTT until they reached stable baseline performance on stimulus duration 1 s (accuracy \>80% correct choice and \<20% errors of omission during the last five sessions). Subsequently, the effects of varenicline were assessed using a Latin square design, and tests were conducted twice a week, on Tuesdays and Fridays. On intermediate days, rats were trained normally without being treated with varenicline. Following the tests with varenicline, animals were trained for an additional week and tested under increased attentional demand by reducing the stimulus duration to 0.5 s. Subsequently, under these conditions, the effect of 1.5 mg/kg varenicline was tested.

Drugs {#Sec12}
-----

Nicotine hydrogen tartrate salt (Sigma, St Louis, MO, USA) was dissolved in sterile saline, and the pH of the solution was adjusted to ±7.4 with diluted NaOH. The nicotine dose is expressed as free base weight. For all alcohol solutions used, 96% laboratory alcohol (Interchema, Oosterzee, the Netherlands) was diluted with water to reach the appropriate concentrations. Varenicline (kindly provided by Solvay Pharmaceuticals, Weesp, the Netherlands) was suspended in a 1% methylcellulose--5% mannitol solution, and the pH was adjusted to 7.9. In all studies, varenicline was administered intraperitoneally with an injection volume of 2 ml/kg, 30 min before testing, and doses were 0.5, 1.5 and 2.5 mg/kg based on previous studies (Rollema et al. [@CR41]; Steensland et al. [@CR47]).

Statistical analyses {#Sec13}
--------------------

All statistical analyses were performed using the Statistical Package for the Social Sciences version 15.0 (SPSS Inc., Chicago, IL, USA), and all data are displayed as mean ± SEM. The homogeneity of variance across groups was determined using Mauchly\'s tests for equal variances and in case of violation of homogeneity, corrected Huynh--Feldt degrees of freedom and resulting more conservative probability values were used for subsequent analyses. In case of statistically significant main effects, further post hoc comparisons were conducted using Student--Newman--Keuls tests. The level of probability for statistically significant effects was set at 0.05.

For the self-administration data, the dependent variables (i.e. total number of nose poke responses in the active and inactive hole and number of reinforcers) were analyzed using a repeated measures analysis of variance (ANOVA) with varenicline doses as within-subject factor. For the relapse experiments, a between-subject design was employed; thus, the different doses of varenicline served as between-subject factors. Data obtained in the 5-CSRTT were subjected to repeated measures ANOVA with varenicline treatment as a within-subject factor.

Results {#Sec14}
=======

Experiment 1: nicotine self-administration {#Sec15}
------------------------------------------

To investigate the effects of varenicline on nicotine self-administration, 16 rats were trained to nose-poke for intravenous nicotine infusions in the presence of audiovisual cues. Six animals were excluded because they did not meet the selection criteria or had clogged catheters. Varenicline treatment had an overall main effect on the total number of active nose pokes (*F*(3,27) = 36.04, *p* \< 0.001), and further post hoc analyses revealed that 1.5 and 2.5 mg/kg varenicline significantly reduced nicotine self-administration compared to vehicle (Fig. [1a](#Fig1){ref-type="fig"}). Varenicline treatment also affected the total number of inactive responses (*F*(3,27) = 2.98, *p* \< 0.05). Post hoc analyses revealed that inactive responding did not differ from vehicle treatment for any of the varenicline doses; however, the 2.5-mg/kg dose significantly reduced the number of inactive responses compared to 0.5 mg/kg varenicline. Fig. 1Effects of varenicline on self-administration of **a** nicotine, **b** alcohol and **c** sucrose (inactive responses sucrose self-administration (mean ± SEM): 0.0 g/kg, 3 ± 1.6; 0.5 g/kg, 1.7 ± 0.5; 1.5 g/kg, 0.1 ± 0.1; 2.5 g/kg, 0.1 ± 0.1). \**p* \< 0.05 significant difference with respect to 0.0 g/kg group

Experiment 2: alcohol self-administration {#Sec16}
-----------------------------------------

In experiment 1, varenicline was able to dose-dependently reduce nicotine self-administration. To investigate its effects on alcohol self-administration, a separate group of 16 animals was trained. Twelve animals met our selection criteria. Varenicline treatment had an overall main effect on operant self-administration of alcohol (*F*(3,33) = 7.65, *p* \< 0.001), and post hoc analyses revealed that 1.5 and 2.5 mg/kg varenicline significantly reduced alcohol self-administration compared to vehicle (Fig. [1b](#Fig1){ref-type="fig"}). In addition, a main effect of varenicline treatment was also found on the total number of inactive responses (*F*(3,33) = 3.96, *p* \< 0.05). Post hoc analyses revealed that inactive responding did not differ from saline treatment for any of the varenicline doses; however, both treatment with 1.5 and 2.5 mg/kg varenicline significantly reduced the number of inactive responses compared to treatment with 0.5 mg/kg varenicline.

Experiment 3: sucrose self-administration {#Sec17}
-----------------------------------------

To assess whether varenicline treatment selectively affects nicotine and alcohol self-administration over responding for natural reinforcers, eight rats were trained to nose-poke for 10% sucrose reinforcers in the presence of audiovisual cues. All animals acquired stable self-administration of sucrose. Varenicline had an overall main effect on operant self-administration of sucrose (*F*(3,21) = 6.61, *p* \< 0.01), and post hoc analyses revealed that all varenicline doses significantly increased sucrose self-administration compared to vehicle (Fig. [1c](#Fig1){ref-type="fig"}). In addition, a main effect of varenicline treatment was also found for the total number of inactive responses (*F*(3,21) = 3.49, *p* \< 0.05). Post hoc analyses revealed that only treatment with 2.5 mg/kg varenicline significantly reduced the number of inactive responses compared to vehicle treatment.

Experiment 4: nicotine relapse {#Sec18}
------------------------------

To assess whether varenicline would be protective against relapse to nicotine seeking, we investigated its effects on cue-induced relapse after extinction. Fifty-four animals met the selection criteria and were divided into four groups (vehicle (*n* = 18), 0.5 mg/kg (*n* = 12), 1.5 mg/kg (*n* = 12) or 2.5 mg/kg (*n* = 12) varenicline). The different experimental groups displayed equivalent levels of active responding during the last 2 days of training and extinction (data not shown). Varenicline had an overall main effect on cue-induced relapse to nicotine self-administration (*F*(3,50) = 4.28, *p* \< 0.01; Fig. [2a](#Fig2){ref-type="fig"}). Further comparisons revealed that the 0.5-mg/kg dose increased responding for nicotine cues compared to vehicle and 2.5 mg/kg (*p* \< 0.05). Treatment with 2.5 mg/kg varenicline significantly reduced the number of active responses compared to treatment with 0.5 mg/kg varenicline. A treatment effect was also found for inactive responses (*F*(3,50) = 2.98, *p* \< 0.05). Post hoc analyses revealed an increase in inactive responding in the 0.5-mg/kg varenicline group compared to all other groups. Fig. 2Effects of varenicline on cue-induced reinstatement of **a** nicotine and **b** alcohol seeking. \**p* \< 0.05 significant difference with respect to 0.0 g/kg group

Experiment 5: alcohol relapse {#Sec19}
-----------------------------

Before the cue-induced relapse test was conducted, the different experimental groups (vehicle (*n* = 10), 0.5 mg/kg (*n* = 10), 1.5 mg/kg (*n* = 10) or 2.5 mg/kg (*n* = 10) varenicline) displayed equivalent levels of active responding during the last 2 days of training and extinction (data not shown). Varenicline had an overall main effect on relapse to alcohol seeking (*F*(3,36) = 13.63, *p* \< 0.001), and post hoc analyses revealed that 1.5 and 2.5 mg/kg varenicline significantly reduced relapse to alcohol seeking compared to vehicle, whereas the 0.5 mg/kg dose seemed to induce a slight, but non-significant increase in alcohol seeking (*p* = 0.07; Fig. [2b](#Fig2){ref-type="fig"}). Varenicline treatment did not affect inactive responding (*F*(3,36) = 0.60, *p* = 0.618).

Experiment 6: 5-CSRTT {#Sec20}
---------------------

To assess putative cognitive-enhancing effects of varenicline, 16 rats were trained in the 5-CSRTT. Varenicline treatment had a main effect on attention (*F*(3,45) = 3.92, *p* \< 0.05), premature responding (*F*(3,45) = 3.15, *p* \< 0.05) and correct response latency (*F*(3,45) = 2.28, *p* \< 0.05), but not on the number of omissions (*F*(3,45) = 2.28, *p* = 0.1; Fig. [3](#Fig3){ref-type="fig"}). Post hoc analyses showed that the number of premature responses was increased by the 0.5- and 1.5-mg/kg dose of varenicline (*p* \< 0.05), whereas the 2.5-mg/kg dose tended to increase the number of premature responses (*p* = 0.06). With regard to the effects on attention and correct response latencies, post hoc analyses revealed no significant effects of any dose compared to vehicle. However, 2.5 mg/kg varenicline did increase correct response latency compared to the 0.5- and 1.5-mg/kg dose. Fig. 3Effects of varenicline on 5-choice serial reaction time performance. The following behavioural measures are presented: **a** percentage correct responses (attention), **b** number of premature responses (impulsivity), **c** number of omissions and **d** latency of correct responses. \**p* \< 0.05 significant difference with respect to 0.0 g/kg group

To investigate whether varenicline would enhance performance under conditions of increased attentional load, the effect of 1.5 mg/kg varenicline was tested in combination with a reduced stimulus duration of 0.5 s. Increasing the attentional load by reducing the stimulus duration from 1 to 0.5 s reduced accuracy (*F*(1,15) = 36.94, *p* \< 0.001), shortened response latencies (*F*(1,15) = 13.62, *p* \< 0.01) and increased omission rate (*F*(1,15) = 69.40, *p* \< 0.001), whereas premature responding remained unaffected (*F*(1,15) = 2.3, *p* = 0.15; Fig. [4](#Fig4){ref-type="fig"}). In accordance with the aforementioned results, 1.5 mg/kg varenicline increased the number of premature responses (*F*(1,15) = 27.45, *p* \< 0.001), but did not alter accuracy (*F*(1,15) = 1.42, *p* = 0.25) or correct response latencies (*F*(1,15) = 1.65, *p* = 0.20). A reduction of omissions was seen after varenicline treatment (*F*(1,15) = 15.11, *p* \< 0.001). Furthermore, a treatment × stimulus duration interaction effect for correct response latency was found (*F*(1,15) = 6.00, *p* \< 0.05). Post hoc analyses indicated that the reduction of correct response latencies induced by increased attentional load was less pronounced following varenicline treatment. None of the other parameters showed a treatment × stimulus duration interaction (accuracy, *F*(1,15) \< 1, *p* = 0.85; omissions, *F*(1,15) = 1.83, *p* = 0.20); premature responding, *F*(1,15) = 1.89, *p* = 0.15). Fig. 4Effects of varenicline (1.5 mg/kg) on 5-choice serial reaction time performance under increased attentional load by reduced stimulus duration. The following behavioural measures are presented: **a** percentage correct responses (attention), **b** number of premature responses (impulsivity), **c** number of omissions and **d** latency of correct responses. \**p* \< 0.05 significant difference with respect to 0.0 g/kg group. \#*p* \< 0.05 significant difference with respect to stimulus duration 1.0 s

Discussion {#Sec21}
==========

In the present study, we evaluated the effects of varenicline on both motivational processes (nicotine, alcohol and sucrose seeking) and cognitive functions (visuospatial attention and inhibitory response control) in rats. We confirm earlier observations demonstrating that varenicline attenuates nicotine and alcohol self-administration (O\'Connor et al. [@CR36]; Rollema et al. [@CR41]; Steensland et al. [@CR47]). In contrast, self-administration of the natural reinforcer sucrose was increased by varenicline. Importantly, we demonstrate for the first time that varenicline dose-dependently reduces cue-induced relapse to alcohol seeking. Interestingly, cue-induced relapse to nicotine seeking was not affected by the higher doses, and the lowest dose of varenicline (0.5 mg/kg) increased responding for nicotine-associated cues. At the cognitive level, we show that varenicline reduces inhibitory response control without affecting measures of visuospatial attention in a 5-choice serial reaction time task (5-CSRTT).

In the treatment of drug addiction, relapse after abstinence represents a major problem. Ideally, pharmacotherapies for drug addiction would aid the cessation of drug intake and prevent relapse. As both preclinical and clinical data indicate that varenicline may potentially posses both characteristics (Gonzales et al. [@CR18]; Jorenby et al. [@CR22]; O\'Connor et al. [@CR36]; Patterson et al. [@CR37]; Rollema et al. [@CR41], [@CR42]; Steensland et al. [@CR47]; Tonstad et al. [@CR49]; Tonstad [@CR48]), we determined the anti-relapse properties of varenicline in a so-called self-administration--reinstatement model (Shaham et al. [@CR44]). Remarkably, we found that varenicline strongly attenuated cue-induced alcohol seeking at the same doses that reduced alcohol self-administration. This finding suggests that varenicline has putative protective effects against relapse to alcohol use, an important addition to the growing body of evidence that underlines the potential of varenicline as a treatment for alcohol use disorders.

How varenicline modulates the neurobiological mechanisms that mediate cue-induced relapse to alcohol seeking remains to be unravelled. Pharmacological studies have identified several neurotransmitter systems that appear to be involved in alcohol relapse, including the glutamate, opioid, serotonin and dopamine system. In particular, activation of the mesolimbic dopamine system and alterations in excitatory amino acid neurotransmission may underlie relapse to alcohol seeking (Le and Shaham [@CR25]). Since varenicline was reported to affect dopamine release in the nucleus accumbens (Coe et al. [@CR6]; Ericson et al. [@CR15]; Rollema et al. [@CR41]), it may alter relapse to alcohol seeking by modulating dopaminergic neurotransmission in the mesolimbic pathway.

In a separate experiment, we assessed the effects of varenicline on cue-induced relapse to nicotine seeking. Remarkably, we found that varenicline, at doses that diminished relapse to alcohol seeking, did not reduce cue-induced relapse to nicotine seeking. These results are consistent with recent findings of O\'Connor et al. ([@CR36]). Furthermore, we found enhanced cue-induced relapse at a dose of 0.5 mg/kg. Interestingly, a similar but non-significant (*p* = 0.07) effect was seen on alcohol seeking. Thus, it seems that varenicline affects cue-induced relapse in a bimodal fashion. A possible explanation may be that the anti-relapse effect is mediated by receptors other than the α4β2 nACh subtype that are activated at higher doses, while at low doses, varenicline induces a priming effect via α4β2 nACh receptors. Indeed, varenicline was shown to be a (partial) agonist for other nACh receptor subtypes, such as α7 and at higher doses α3β4, α3β2 and α6 receptors, albeit with much lower affinity (Coe et al. [@CR6]; Mihalak et al. [@CR30]). Hence, varenicline may activate additional nAch receptor subtypes at 1.5 and 2.5 mg/kg (Rollema et al. [@CR42]).

Regarding varenicline\'s effects on self-administration, our findings confirm that varenicline dose-dependently attenuates nicotine self-administration. Substantial evidence indicates that varenicline may affect nicotine self-administration by reducing nicotine-induced mesolimbic dopamine release (Coe et al. [@CR6]; Rollema et al. [@CR41]). In agreement with results from Steensland et al. ([@CR47]), our data suggest that varenicline has a comparable effect on alcohol self-administration. Similarly, co-administration of varenicline and alcohol counteracted each other\'s respective enhancing effect on dopamine levels in the nucleus accumbens (Ericson et al. [@CR15]). Nonetheless, it remains to be determined whether varenicline\'s attenuating effect on alcohol and nicotine self-administration is mediated by the same molecular mechanisms. As mentioned before, varenicline is known to have limited selectivity for different nACh receptor subtypes (Coe et al. [@CR6]; Mihalak et al. [@CR30]). Some of these receptor subtypes are implicated in the reinforcing effects of alcohol (Chastain [@CR4]; Davis and de Fiebre [@CR8]; Ericson et al. [@CR15]; Jerlhag et al. [@CR21]; Larsson et al. [@CR24]; Lof et al. [@CR27]). Particularly, the α3β4 nAch receptor seems a likely candidate for the modulation of alcohol intake (Chatterjee et al. [@CR5]). Therefore, we cannot exclude the notion that varenicline differentially mediates its effects on nicotine and alcohol self-administration via receptors other than the α4β2 nACh receptor.

To determine whether the attenuating effects of varenicline were selective for alcohol and nicotine and/or due to a reduced ability to make an operant response, we assed its effects on operant responding for the natural reinforcer sucrose. Interestingly, sucrose self-administration was augmented by varenicline at doses that significantly reduced nicotine and alcohol self-administration. Previous studies investigating intake of natural reinforcers have not reported such effects (O\'Connor et al. [@CR36]; Steensland et al. [@CR47]). Varenicline was however reported to increase responding for food delivery in rats trained on a variable interval reinforcement schedule (Rollema et al. [@CR41]). A role for nACh receptors in sucrose seeking, however, is not supported by previous data, i.e. nACh receptor agonists and antagonists have not been reported to attenuate sucrose intake (Ford et al. [@CR16]; Hendrickson et al. [@CR20]; Nadal et al. [@CR32]; Neugebauer et al. [@CR33]; Steensland et al. [@CR47]).

Collectively, these findings imply the following. First, that varenicline selectively attenuates self-administration of alcohol and nicotine, an effect that does not generalize to self-administration of food or sucrose. In fact, our findings suggest that varenicline affects operant responding for natural reinforcers and addictive substances, i.e. nicotine and alcohol, in opposite directions. Second, as varenicline treatment did not impair sucrose self-administration, varenicline\'s effects on consumption of addictive substances are most probably due to changes in the motivational domain, rather than impaired abilities to perform an operant response.

In humans, varenicline was shown to enhance cognitive functioning during abstinence of smoking/drinking. Although the effects were small, varenicline improved sustained attention (as measured by the Penn Continuous Performance Task) and working memory (as measured by the letter N-back task; Patterson et al. [@CR37]). Furthermore, recent rodent studies show that varenicline may ameliorate alcohol-induced cognitive deficits in acquisition of contextual and cued associative learning in mice (Gulick and Gould [@CR19]) and improve attentional performance in a sustained attention task with distractor stimuli in rats (Rollema et al. [@CR42]). We used the 5-choice serial reaction time task (5-CSRTT) to further explore the effects of varenicline on cognition. Previous research from our and other laboratories revealed that nicotine positively affects cognitive function as measured in the 5-CSRTT by (1) enhancing sustained attention under certain conditions, (2) decreasing response latency and (3) reducing the number of omissions. On the other hand, nicotine deteriorates inhibitory control in this task as measured by an increase in premature responding (Blondel et al. [@CR2]; Day et al. [@CR9]; Mirza and Stolerman [@CR31]; van Gaalen et al. [@CR50]). In the current study, we found no evidence for cognitive-enhancing effects of varenicline. However, varenicline increased premature responding, albeit to a lesser extent than nicotine (Blondel et al. [@CR2]; Mirza and Stolerman [@CR31]; van Gaalen et al. [@CR50]). This effect may result from enhanced dopaminergic neurotransmission in the mesolimbic pathway induced by nACh receptor activation in the nucleus accumbens or ventral tegmental area (Di Chiara and Imperato [@CR11]; Marshall et al. [@CR28]; Nisell et al. [@CR35]; Wonnacott [@CR51]), that in turn has been demonstrated to modulate premature responding in the 5-CSRTT (Cole and Robbins [@CR7]; Pattij et al. [@CR38]). It should be noted here that detrimental effects of varenicline on inhibitory response control may be unfavourable during treatment in humans, as previous research from our laboratory has associated poor inhibitory response control with an enhanced motivation to initiate and maintain nicotine self-administration in rats (Diergaarde et al. [@CR12]). Likewise, in line with these preclinical findings, diminished inhibitory control has been demonstrated to predict unsuccessful smoking cessation in abstinent smokers (Krishnan-Sarin et al. [@CR23]). Interestingly, recent findings from our laboratory suggest that under comparable conditions, no such association exists between inhibitory response control and alcohol self-administration in rats (Diergaarde, unpublished). The strong relationship between impulsivity and nicotine, but not alcohol seeking, together with the observation that varenicline diminishes inhibitory control may partly explain the differential effects of this compound on relapse to alcohol and nicotine seeking.

We also tested varenicline in combination with a reduced stimulus duration (0.5 s instead of 1 s) to assess its effects on performance under increased attentional load. Compared to saline treatment, varenicline was unable to improve attentional performance under these challenging conditions. This seems to contradict previous data demonstrating that varenicline significantly improved the capacity to attenuate impaired performance under challenging distractor conditions in a sustained attention task (Rollema et al. [@CR42]). Specific differences between the 5-CSRTT and the sustained attention task may explain this discrepancy. In particular, in the sustained attention task, an auditory stimulus was used to reduce the discriminability of a visual cue, whereas in the 5-CSRTT, the signal duration of a visual cue was reduced. It is possible that varenicline reduces the impact of a distractor on signal detection, but does not improve sustained attention. Taken together, varenicline\'s effects on cognitive functions as measured in the 5-CSRTT seem limited and less pronounced than the effects of nicotine, consistent with its lower efficacy at the nACh receptor.

In summary, this is the first report to demonstrate that, in rats, varenicline attenuates cue-induced alcohol seeking. Furthermore, at lower doses, varenicline may facilitate nicotine seeking. As was previously shown, varenicline may selectively reduce voluntary nicotine and alcohol intake. Moreover, varenicline has limited effects on cognitive functioning as measured by the 5-CSRTT, although varenicline may somewhat reduce inhibitory response control. Such a behavioural pharmacological profile emphasizes varenicline\'s potential as a pharmacotherapeutical agent in the treatment of alcohol dependence.
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